BioRestorative Therapies(BRTX)
MELVILLE, NYBiotechnology
Focus: BioRestorative Therapies is a public biotech company focused on autologous stem cell therapy for degenerative diseases, currently advancing BRTX-100 for lumbar disc disease. The company is in early-stage development with minimal revenue and a single Phase 2 program.
Profile data last refreshed 36m ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
0
About BioRestorative Therapies
AI assessmentNot HiringNo open roles listed right now. Follow BioRestorative Therapies to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from BioRestorative Therapies's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Revenue
$401K
Pipeline & Clinical Trials
BRTX-100
Lumbar Disc DiseaseClinical Trials (1)
NCT04042844A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
Phase 2Help build intelligence for BioRestorative Therapies
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.